Why Are Endometrial Cancer Outcomes Worse for Black Women? An Evidence Map

Black women face a substantially higher death rate from endometrial cancer than White women. Research points to several contributing factors, including more aggressive tumor types, differences in diagnostic evaluation, and barriers to timely treatment.

Tumor characteristics explain part of the gap. They do not explain every difference in care or outcome.

For patients, one issue deserves immediate attention. Bleeding after menopause needs prompt evaluation, and an ultrasound result alone may not provide enough reassurance.

What the Mortality Gap Actually Measures

The American Cancer Society's 2026 endometrial cancer statistics describe a death rate in Black women that is nearly twice the rate in White women.

A mortality rate counts deaths across a population. It is different from the chance that an individual patient will die after diagnosis. Your own outlook depends on the cancer's stage, subtype, molecular features, treatment, and other health factors.

The disease categories also matter. Endometrial cancer starts in the uterine lining. Some national reports group it with other cancers of the uterine body, including uterine sarcomas. Statistics for that broader group should not be presented as though they describe only one endometrial cancer subtype.

Why “Black Women Get It Less Often” Is Too Simple

Older comparisons often described lower incidence in Black women. That is an incomplete way to explain today's disparity.

The American Cancer Society's 2025 report on cancer in Black people describes similar unadjusted uterine cancer incidence in Black and White women, with higher incidence in Black women after accounting for hysterectomy.

That adjustment matters because someone whose uterus has been removed is no longer at risk of developing a new cancer in its lining. Counting that person in the population used to calculate incidence can make the rate look lower.

The comparison changes with the study period, cancer category, and population being measured. It should not be used to reassure a Black patient that abnormal bleeding is unlikely to matter.

Why Bleeding Is Central to Earlier Diagnosis

Endometrial cancer often causes abnormal vaginal bleeding. Bleeding or spotting after menopause is particularly important, even if it happens only once.

Before menopause, bleeding between periods, unusually heavy bleeding, or a persistent change in the bleeding pattern can also require assessment.

There is no routine screening test recommended for people at average endometrial cancer risk who have no symptoms. The American Cancer Society's early detection guidance therefore emphasizes reporting symptoms. People with certain inherited risks need a separate discussion about surveillance and prevention.

Evaluating bleeding is diagnostic care, not routine screening. A patient should not have to wait until her next preventive visit to report it.

Tumor Type and Stage Explain Part of the Difference

Endometrial cancers do not all behave alike.

Some lower-grade endometrioid cancers have a relatively favorable outlook when found early. Serous carcinoma, carcinosarcoma, and other high-risk cancers can behave more aggressively. Grade, stage, and molecular classification provide different information and should not be treated as interchangeable.

A molecular study comparing endometrial cancers in Black and White patients found differences in the distribution of tumor characteristics, including molecular subtypes associated with poorer outcomes.

Those findings support testing and treating the actual tumor. They do not mean that race determines an individual's cancer biology or prognosis.

Stage also matters. Cancer confined to the uterus generally presents different treatment possibilities from cancer that has spread. But a later-stage diagnosis does not, by itself, establish that an earlier clinician missed a detectable cancer.

The record must show what symptoms and findings were present, what evaluation was indicated, and whether an earlier diagnosis was reasonably possible.

Why Ultrasound Alone Can Miss Important Disease

Transvaginal ultrasound can show the thickness and appearance of the uterine lining. It does not examine tissue under a microscope.

An endometrial biopsy collects tissue for pathology. The two tests answer different questions.

A 2024 diagnostic study involving Black patients found that using endometrial thickness thresholds to decide who needed further evaluation could miss cancers. The study involved patients who underwent hysterectomy, so its findings should not be converted into a personal risk percentage for everyone with bleeding.

The practical concern is false reassurance. A thin lining, an unclear measurement, or another finding on the scan should not automatically end the investigation when the clinical situation calls for tissue evaluation.

ACOG Updated Its Guidance in 2026

ACOG's updated postmenopausal bleeding guidance recommends both transvaginal ultrasound and endometrial tissue sampling as part of the initial evaluation for most patients with postmenopausal bleeding.

This revises the earlier approach that allowed ultrasound alone for some patients with a thin endometrial lining.

ACOG specifically identifies the relevance to Black women, who may have aggressive cancers without the ultrasound abnormalities clinicians expect.

“Most patients” does not mean every patient needs an identical procedure regardless of circumstances. The clinician should explain the recommended evaluation, its limitations, and any reason for a different approach.

The recommendation concerns postmenopausal bleeding. It should not be applied automatically to every person having heavy periods before menopause.

Treatment Access Matters After Diagnosis

A diagnosis does not eliminate barriers to care.

A 2025 study of time to surgery for endometrial cancer found higher odds of surgical treatment delays among Black patients than White patients across the broad cancer groups studied.

A 2026 study of advanced or recurrent endometrial cancer also found that disparities in treatment initiation and survival persisted and were influenced by socioeconomic circumstances.

These are observational findings. They do not establish that every treatment interval is inappropriate or that one factor caused the entire mortality gap.

They do show why timely care must include more than making a diagnosis. Patients need access to the appropriate specialist, an explained treatment plan, and follow-up when referrals or appointments do not happen.

Insurance authorization, transportation, work schedules, and caregiving responsibilities are practical issues the team can ask about when arranging that care.

New York Filing Deadlines Require a Separate Review

Under CPLR 214-a, the ordinary medical malpractice filing period is two years and six months from the alleged malpractice or the last qualifying continuous treatment.

For negligent failure to diagnose cancer or a malignant tumor, the statute provides a special calculation involving knowledge of both the alleged negligence and the resulting injury.

The discovery-based provision contains a seven-year limit, and the statute also provides a qualifying continuous-treatment alternative.

The date a patient learned she had cancer is not automatically the date she knew or should have known about negligent care.

Public-entity notice requirements and other rules may create different obligations. Preserve the records and obtain a deadline assessment promptly rather than assuming the cancer discovery provision gives unlimited time.

Discuss Concerns About Missed Bleeding or Delayed Follow-Up

If you believe your symptoms were dismissed or your diagnosis was delayed, gather the relevant office notes, ultrasound reports, pathology results, referrals, and messages.

Porter Law Group can review concerns about a delayed endometrial cancer diagnosis and explain the legal issues involved.

Call 833-888-LATE, email info@porterlawteam.com, or request a review of your endometrial cancer care.

This article provides general educational information, not medical or legal advice. Report abnormal bleeding to a health care professional and continue recommended evaluation and treatment. Do not delay medical care while seeking legal advice.

Attorney Advertising. Reading this article or contacting the firm does not create an attorney-client relationship.

Frequently Asked Questions

Does the Higher Mortality Rate Predict What Will Happen to Me?

No. A population death rate cannot predict an individual patient's outcome. Your cancer's stage, grade, histologic and molecular subtype, treatment, and overall health all matter. The disparity identifies an important public health problem, but it should not replace an explanation of your own pathology and treatment options.

Can a Normal Ultrasound Rule Out Endometrial Cancer?

Not reliably in every patient. Ultrasound measures and images the uterine lining, while tissue sampling examines cells for disease. ACOG's 2026 guidance recommends both tests for most patients with postmenopausal bleeding. Ask what your ultrasound actually established and whether tissue evaluation is still needed in your circumstances.

Can Fibroids Explain Bleeding Without Any Further Evaluation?

Sometimes fibroids explain bleeding, but their presence does not automatically exclude another cause. Menopausal status, the bleeding pattern, risk factors, imaging, and any tissue findings matter. If bleeding occurs after menopause or continues despite treatment, ask what evaluation is needed rather than assuming the fibroid settles the question.

Is a Pap Test a Screening Test for Endometrial Cancer?

No. A Pap test is used to screen for cervical abnormalities, not to reliably exclude cancer in the uterine lining. A normal Pap result does not explain postmenopausal bleeding or replace an indicated endometrial evaluation. Tell your clinician about bleeding even if your cervical screening results have been normal.

Does a Diagnosis After Months of Bleeding Prove Malpractice?

No. The timeline raises questions, but the records must establish what care was indicated, whether the provider departed from accepted practice, and what harm the departure caused. Review may focus on symptom reports, test completion, inadequate samples, communicated results, and whether earlier diagnosis would have changed the outcome.